TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33449924
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment in years 1 and 3 without treatment in-between
Study: 32414398
Drug: Ivermectin 3-monthly
Normalized name: ivermectin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 3-monthly (150 µg/kg or 800 µg/kg)
Study: 32414398
Drug: Ivermectin annually
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin annually (150 µg/kg or 800 µg/kg)
Study: 35930126
Drug: Galcanezumab (GMB)
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab (GMB) 120 mg with 240 mg loading dose
Study: 33953828
Drug: IL-37 in
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-37 in the highest quartile (>405.3 pg/ml)
Study: 33486528
Drug: Higher time-averaged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher time-averaged on-treatment systolic blood pressure (median: <138.3 vs. ≥138.3 mmHg)
Study: 35847998
Drug: 2-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-weekly docetaxel 50 mg/m2
Study: 35847998
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel 75 mg/m2
Study: 34121334
Drug: Petrolatum applied
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum applied twice daily for 8 weeks
Study: 33345910
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg aspirin daily (Low-Risk Aspirin trial)
Study: 33345910
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg aspirin daily (High-Risk Aspirin trial)
Study: 33345910
Drug: Placebo (Low-Risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Low-Risk Aspirin trial)
Study: 33345910
Drug: Placebo (High-Risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (High-Risk Aspirin trial)
Study: 32661104
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care service (intervention group)
Study: 35365457
Drug: Ultrasound-guided stellate
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided stellate ganglion block (SGB) with 7 mL 0.5% ropivacaine
Study: 35079071
Drug: TM+V (vibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM+V (vibration applied with 5.2±0.5 g-forces, 102.2±2.6 Hertz for 3 min)
Study: 35767699
Drug: High-glucose mixed-nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose mixed-nutrient meal (1.1 g glucose/kg body wt)
Study: 35428992
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily for 3 days
Study: 35428992
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thrice daily for 5 days
Study: 35428992
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg thrice daily for 3 days
Study: 35428992
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg thrice daily for 5 days
Study: 35428992
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg thrice daily for 5 days
Study: 35428992
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thrice daily for 3 days
Study: 36134834
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (suboptimal responders)
Study: 36134834
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (suboptimal responders with LDL < 55 mg/dL)
Study: 33460320
Drug: Isradipine 5-mg
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5-mg twice daily
Study: 36385453
Drug: Emulsified isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emulsified isoflurane (30 mg/kg, 12% emulsified isoflurane)
Study: 36385453
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg, 0.8% propofol)
Study: 34708996
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90)
Study: 34708996
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90)
Study: 32451660
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation 25 mg/8 h for two consecutive cycles before induction of ovulation
Study: 35319845
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with moxibustion on the affected side for 30 min once daily for 4 weeks.
Study: 35319845
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Zusanli(ST36), Neixiyan(EX‐LE4), Heding(EX‐LE2) and Xuanzhong(GB39) for 30 min once daily for 4 weeks.
Study: 32231295
Drug: JNJ-67953964 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-67953964 (10 mg)
Study: 32638239
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment (LLLT)
Study: 33052759
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of sorafenib (400 mg twice per day orally, amended to 400 mg daily)
Study: 34362410
Drug: multidisciplinary transition
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multidisciplinary transition of care program and medications’ data transfer between inpatient and outpatient caregivers
Study: 35843080
Drug: alectinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: alectinib 300 mg
Study: 35843080
Drug: crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: crizotinib 250 mg
Study: 34089596
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (three 3-week cycles of CAPOX, four 2-week cycles of FOLFOX or FOLFORI) followed by neoadjuvant chemoradiotherapy and surgery
Study: 34089596
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
Study: 32268000
Drug: RO7020531 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (150 mg, multiple ascending doses every other day)
Study: 32268000
Drug: RO7020531 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (various doses from 40 mg to 170 mg)
Study: 32268000
Drug: RO7020531 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (100 mg or above)
Study: 35617911
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving disability benefits, lower anxiety and/or depression scores, shorter duration, younger age at DS onset, employment, fewer symptoms, higher educational qualification, stronger belief in the diagnosis and in CBT as a 'logical' treatment
Study: 32703316
Drug: medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication plus DIT
Study: 32703316
Drug: medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication plus active control psychotherapy
Study: 34703180
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin (40 mg, daily) for 10 days
Study: 32926010
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg orally three times/week for 12 weeks)
Study: 33657293
Drug: Targeted 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted 20% human albumin solution for up to 14 days or until discharge; median total infusion of 200 g (IQR, 140 to 280) per patient.
Study: 33657293
Drug: Standard care;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care; median total infusion of 20 g (IQR, 0 to 120) per patient.
Study: 34389257
Drug: Pharmacist-administered HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-administered HPV vaccine series completion
Study: 34389257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group completing the HPV vaccine series at their FQHC
Study: 36127081
Drug: Ecological Momentary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecological Momentary Intervention 'SmartSafe' in addition to treatment as usual (TAU)
Study: 36127081
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) with Ecological Momentary Assessment (EMA) monitoring
Study: 34841676
Drug: Tele-exercise classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-exercise classes delivered via Zoom, 60-min weekly sessions by a trained exercise therapist for 3-6 months post-surgery.
Study: 32379102
Drug: 5% monolaurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% monolaurin vaginal gel
Study: 32379102
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo gel
Study: 35661029
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (Control group)
Study: 32332635
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment measures
Study: 615988346
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (100 mg/mL)
Study: 32448796
Drug: Computerised decision-support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised decision-support tool to assist with antidepressant choices
Study: 33075789
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (100 mg in 100 mL normal saline over 10 min)
Study: 33075789
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g in 100 mL normal saline over 10 min)
Study: 35409815
Drug: Maintain daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain daily habits
Study: 35486088
Drug: Misoprostol tablets
Normalized name: Misoprostol Tablets
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol tablets (test product)
Study: 35486088
Drug: Cytotec (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotec (200 μg) (reference product)
Study: 34596484
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg OD
Study: 34596484
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg OD
Study: 34596484
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg OD
Study: 39236736
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab
Study: 36110857
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) during primary HIV infection (PHI)
Study: 34375514
Drug: L. edodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. edodes bars (shiitake bars)
Study: 32949011
Drug: L. sakei
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. sakei proBio65 live cells (1 × 10^10 cells/day for 12 weeks)
Study: 32949011
Drug: L. sakei
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. sakei proBio65 dead cells (1 × 10^10 cells/day for 12 weeks)
Study: 32949011
Drug: L. sakei
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. sakei proBio65 live cells
Study: 32949011
Drug: L. sakei
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. sakei proBio65 dead cells
Study: 35961661
Drug: Procedural rotation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedural rotation (emergency medicine, obstetrics and gynecology)
Study: 33071178
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (metformin alone or in combination with rosiglitazone or intensive lifestyle intervention)
Study: 33421652
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of slow-motion and real-time video demonstration
Study: 35982587
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (8 sessions)
Study: 36129997
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U-100
Study: 32896014
Drug: Patient-centred self-administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centred self-administered acupressure intervention
Study: 34453640
Drug: irinotecan‐alone (irinotecan;
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan‐alone (irinotecan; 150 mg/m2, day 1, q14 days)
Study: 34453640
Drug: paclitaxel‐alone (paclitaxel;
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel‐alone (paclitaxel; 80 mg/m2, days 1, 8, 15, q28 days)
Study: 34453640
Drug: S‐1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 plus irinotecan (irinotecan; 80 mg/m2, days 1, 15, S‐1; 80 mg/m2, days 1-21, q35 days)
Study: 34453640
Drug: S‐1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 plus paclitaxel (paclitaxel; 50 mg/m2, day 1, 8, S‐1; 80 mg/m2, days 1-14, q21 days)
Study: 35257740
Drug: Nebulized poractant
Normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized poractant alfa 200 mg/kg
Study: 35257740
Drug: Nebulized poractant
Normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized poractant alfa 400 mg/kg
Study: 36345917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of photobiomodulation therapy (PBMT) and pulsed electromagnetic field therapy (PEMF)
Study: 36345917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PBMT and PEMF
Study: 35351779
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review with shared decision-making (SDM)
Study: 36100282
Drug: Adjuvant external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant external beam radiotherapy±brachytherapy ± concomitant chemotherapy
Study: 36100282
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment after radical surgery
Study: 32319175
Drug: 10% topical
Normalized name: BP 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% topical sucralfate ointment
Study: 33919799
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant coverage limited to one tooth per individual
Study: 33919799
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant coverage for front teeth
Study: 35538630
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil supplements (2000mg/day)
Study: 33988236
Drug: Oral ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferric maltol 30 mg twice daily
Study: 35273052
Drug: MAMS platform
Normalized name: mAMSA
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAMS platform trials evaluating medications
Study: 35273052
Drug: MAMS platform
Normalized name: mAMSA
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAMS platform trials with repurposed medications as comparison arms
Study: 34281405
Drug: Self-Empowered UL
Normalized name: sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Empowered UL Repetitive Engagement (SURE): individualized, UL self-exercise and use outside therapy for 6 hours/week for 4 weeks
Study: 32423365
Drug: CHW-administered screening
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHW-administered screening questions
Study: 32423365
Drug: GP-administered screening
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP-administered screening questions
Study: 32423365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of questions concerning fever, pain, and discolored drainage
Study: 34128426
Drug: β-glucan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan (6 g/day)
Study: 34128426
Drug: inulin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: inulin (6 g/day)
Study: 35606137
Drug: RED-D (Re-Engineered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RED-D (Re-Engineered Discharge for Depression) - a 12-week post-discharge telehealth intervention including cognitive behavioral therapy, self-management support, and patient navigation.
Study: 35606137
Drug: RED-only (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: RED-only (standard Re-Engineered Discharge without depression treatment)
Study: 33749913
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA, 3.36 g daily
Study: 35026396
Drug: Inhaled nebulized
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulized 30 mg sodium nitrite twice a day for 12 weeks
Study: 33986493
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine (11 g of decaffeinated coffee)
Study: 33986493
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine (5.5 g of caffeinated plus 5.5 g of decaffeinated coffee)
Study: 33986493
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg caffeine (11 g of caffeinated coffee)
Study: 36045392
Drug: Practice change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice change intervention including Brief advice to abstain from alcohol and information about potential risks; referral to phone coaching service for medium-risk and Drug and Alcohol Service for high-risk women.
Study: 34466793
Drug: Emotional Freedom
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotional Freedom Techniques (EFT) applied for 16 weeks in the immediate treatment group (ITG)
Study: 33393364
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Stimulation Therapy (iCST), 40 sessions over 20 weeks
Study: 32538123
Drug: Targeted Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted Behavioral Therapy (TBT)
Study: 33352724
Drug: HFCS-SB (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCS-SB (high fructose corn syrup)
Study: 35534349
Drug: Synergy drug
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy drug eluting stent (DES)
Study: 35534349
Drug: Xience drug
Normalized name: Ruxience
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xience drug eluting stent (DES)
Study: 33320406
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil gel 5%
Study: 33320406
Drug: Topical spironolactone
Normalized name: spironolactone Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spironolactone gel 1%
Study: 33320406
Drug: Combined minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined minoxidil 5% and spironolactone 1% gel
Study: 35597332
Drug: Protocol-based potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based potassium supplementation (oral potassium chloride to maintain serum potassium of 4-5 mEq/L)
Study: 35597332
Drug: Conventional potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional potassium supplementation (reactive supplementation when serum potassium is <3.5 mEq/L)
Study: 32817595
Drug: Cortex Phellodendri
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortex Phellodendri Compound Fluid (CPCF)
Study: 32817595
Drug: Kangfuxin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuxin solution (KFS)
Study: 32250171
Drug: One standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: One standard serving (∼11‐15 g) daily of a preferred alcoholic beverage
Study: 33070469
Drug: Propofol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (10 mg/mL)
Study: 34794685
Drug: β-blocker withdrawal
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker withdrawal (arm A: n = 26)
Study: 34794685
Drug: Continuing β-blocker
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing β-blocker treatment (arm B: n = 26)
Study: 37103592
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise and dietary therapy (PED-t)
Study: 33798751
Drug: Intracoronal bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronal bleaching treatment with 35 % hydrogen peroxide for 40 min (Control group)
Study: 33798751
Drug: Intracoronal bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronal bleaching treatment assisted with Er,Cr:YSGG laser (2780 nm) operating at 1.25 W for 30 s
Study: 33798751
Drug: Intracoronal bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronal bleaching treatment assisted with Er,Cr:YSGG laser (2780 nm) operating at 2.5 W for 30 s